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ABSTRACT  
Aberrant Ras signalling drives numerous cancers 
and drugs to inhibit this are urgently required. This 
compelling clinical need, combined with recent 
innovations in drug discovery including the advent 
of biologic therapeutic agents, has propelled Ras 
back to the forefront of targeting efforts. Activated 
Ras has proved extremely difficult to target 
directly and the focus has moved to the main 
downstream Ras-signalling pathways. In 
particular, the Ras-Raf and Ras-PI3K pathways 
have provided conspicuous enzyme therapeutic 
targets, which were more accessible to 
conventional drug-discovery strategies. The Ras-
RalGEF-Ral pathway is a more difficult challenge 
for traditional medicinal development and there 
have therefore been few inhibitors reported that 
disrupt this axis. We have used our structure of a 
Ral-effector complex as a basis for the design and 
characterization of α-helical stapled peptides that 
bind selectively to active, GTP-bound Ral proteins 
and that compete with downstream effector 
proteins. The peptides have been thoroughly 
characterized biophysically. Crucially, the lead 
peptide enters cells and is biologically active, 
inhibiting isoform-specific RalB-driven cellular 
processes. This therefore provides a starting point 
for therapeutic inhibition of the Ras-RalGEF-Ral 
pathway. 
 
Ras is well-established as the most frequently 
mutated oncogene in human cancer. This small G-
protein cycles between an active GTP-bound state 
and an inactive GDP-bound state. Molecular 
switching between the ‘on’ and ‘off’ states is 
positively regulated by nucleotide guanine 
exchange factors (GEFs)1 and negatively regulated 
by GTPase-activating proteins (GAPs). It is only 
the active, GTP-bound form of the protein that can 
bind to downstream effectors and facilitate signal 
transduction. Mutations in oncogenic Ras result in 
a constitutively active protein that remains fixed in 
the GTP-bound ‘on’ state, leading to unregulated 
activation of downstream pathways. These 
mutations are found in approximately 30% of all 
cancers, with a higher occurrence in specific 
cancer types such as pancreatic (71%) and 
colorectal (45%) (1). This makes Ras a crucial 
cancer therapeutic target; nevertheless, Ras has so 
far evaded direct attempts at inhibition and many 
Ras-driven cancers are currently deemed 
undruggable. Ras signalling has proven difficult to 
disrupt by small, drug-like molecules because its 
activation of downstream cascades is 
accomplished through protein-protein interactions, 
which have traditionally been avoided as drug 
targets due to the large, shallow surfaces involved 
in protein-protein interfaces (2-4). Likewise, there 
are no obvious clefts or small molecule binding 
pockets on Ras and competitive inhibition with the 
nucleotide is unfeasible due to the extremely high 
affinity of GTP binding and its high concentration 
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in the cellular environment (5,6). Logical attempts 
to interfere with critical post-translational 
modifications of Ras, such as inhibition of 
farnesyltransferase, have also proved unsuccessful 
(reviewed in (1,6,7)). More encouragingly, a 
specific Ras variant found in lung cancer, G12C, 
was successfully used in a recent disulphide 
fragment-based screen to identify small molecules 
that covalently modify this precise Ras mutant (8). 
This led to the identification of a potential 
allosteric site that may be targetable in this 
particular mutant. The problems with attacking 
Ras directly have driven a broader search for drug 
targets that will interfere with Ras signalling, with 
a focus on the effector proteins downstream of Ras 
(reviewed in (1,6)). Following Ras activation there 
are several pathways that propagate the cellular 
signal, of which at least five have been implicated 
in oncogenic signalling (9). Of these, the Raf, 
phosphoinositide 3-kinase (PI3K) and RalGEF are 
the best validated (6). Both Raf and PI3K have 
been the object of several drug discovery 
initiatives in recent years, with inhibitors of both 
proteins currently in clinical trials (10,11). 
However, the third pathway, via RalGEFs, has 
been less extensively studied and no therapies 
exist that disrupt this signalling route. Despite this, 
RalA and RalB have been shown to be important 
drivers of cell growth, cell survival and metastasis 
in many human cancers, including bladder, 
melanoma, colorectal and pancreatic (12,13).  
RalGEFs act to activate RalA and RalB, 
themselves small GTPases of the Ras superfamily. 
Like Ras, the Ral proteins cycle between GTP and 
GDP-dependent ‘on’ and ‘off’ states and are 
involved in regulating diverse cellular processes 
including proliferation, motility and maintenance 
of cellular architecture (13). RalA and RalB are 
206 amino acid proteins that are 82% identical, 
with 100% identity in the nucleotide-sensitive 
switch regions (switch 1 and switch 2). 
Intriguingly both GTP-loaded proteins interact 
directly with the same set of downstream effectors 
in vitro, including RLIP76 (or RalBP1), the 
exocyst complex subunits Sec5 and Exo84 and the 
transcription factor ZO-1-associated nucleic-acid-
binding protein (ZONAB) (12). Despite engaging 
the same collection of effector proteins, RalA and 
RalB nevertheless regulate distinct cellular 
functions and play different roles in 
tumourigenesis. This is partly attributable to the 
ability of the effectors themselves to promote 
multiple signalling pathways. For example, both 
Ral isoforms interact with Sec5, which can act as 
an integral member of the exocyst complex, 
controlling exocytosis (14,15), but RalB-Sec5 can 
also engage and activate TBK1 and contribute to 
cancer cell survival (16). Interestingly, although 
RalA and RalB have similar affinities for the 
effectors that have been tested in vitro (17-19), 
they may actually possess different affinities in 
vivo (20), explaining some of their distinct cellular 
functions. Some differences between RalA and 
RalB will be due to the hypervariable C-terminal 
region of the proteins, which is differentially 
phosphorylated (21-23) and ubiquitinated (24), 
resulting in distinctive and specific subcellular 
localization for the two proteins. Differential 
activation and deactivation by the RalGEF and 
RalGAP family may also contribute to differential 
roles for the two Ral isoforms. However, no GEFs 
have been found that discriminate between the two 
Ral isoforms and the one structure of a RalGEF 
with Ral shows that all the contacts with the GEF 
protein are conserved between RalA and RalB 
(25) Similarly, RalGAPs appear to act on both 
isoforms in vitro (26) and in cell lines (27). 
Several studies have been reported that attempt to 
delineate separate cellular roles for RalA and 
RalB. siRNA inhibition experiments showed that 
knockdown of RalB in HeLa, MCF7 and SW480 
cell lines resulted in apoptosis, with no effect 
observed in non-cancerous human cell lines, 
suggesting that tumour cells may become 
dependent on RalB survival pathways (28). 
Inhibition of RalA in these experiments had no 
effect on adherent cells but impaired anchorage-
independent proliferation of cells in suspension. In 
contrast, Lim et al. (29) found that RalA, but not 
RalB, was required for oncogenic transformation 
of human fibroblasts and HEK-HT cells and is 
critical for Ras-driven tumourigenesis. Similar 
effects have been observed in human pancreatic 
cancer and colorectal cancer cell lines and, 
interestingly, RalB appears to be important during 
cell invasion and metastasis of these cancers 
(30,31). The molecular basis of the divergent 
functions of RalA and RalB in both normal and 
malignant cells remains to be elucidated. It is clear 
however that both proteins play key roles in 
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tumourigenesis and cancer progression and are 
therefore potential therapeutic targets.  
The Ral proteins adopt the same overall structural 
fold as Ras and are therefore equally difficult to 
disrupt using small molecules. Small molecules 
that bind to inactive, GDP-bound forms of Ral 
have, however, recently been identified using in 
silico screens (32). Our solution structure of 
RalB·GMPPNP in complex with the Ral-binding 
domain of RLIP76 (RLIP76 RBD) (33) showed 
novel features for a Ras family-effector complex 
and presented an avenue for structure-guided 
design of inhibitors that would target the active, 
GTP-bound form of the Ral proteins. The GTP-
bound form is generated downstream of activated 
Ras, so such inhibitors would bind specifically to 
chronically activated Ral, as would be encountered 
in the disease context. The structures that are 
currently available reveal that most Ras and Ral 
effectors form intermolecular β-sheets with the 
small G protein or interact through loops and 
unstructured regions (34). In stark contrast, the 
RLIP76 RBD adopts a well-structured coiled-coil 
domain, consisting of two α-helices that do not 
significantly change conformation on Ral complex 
formation (33). Mimicry of these helices offers an 
ideal opportunity to simulate effector binding and 
inhibit Ral-effector interactions, stopping 
signalling from Ral proteins and ultimately from 
Ras. Biological validation of this proposition has 
already been reported with the observation that 
overexpression of the RLIP76 RBD can interfere 
with Ral signalling, leading to mislocalization of 
Ral-interacting proteins and prevention of RalA-
dependent anchorage-independent growth 
(14,28,35).  
In a timely confluence, the mimicry and 
stabilization of α-helices has been an emerging 
area in inhibitor design in recent years, particularly 
through the use of chemically ‘stapled’ peptides. 
The introduction of a staple confers multiple, 
advantageous, drug-like qualities on the peptides: 
the staple stabilizes the α-helical conformation of 
small peptides leading to an increase in binding 
affinity, it improves the cell penetrating ability of 
the peptide and it enhances the resistance of the 
peptide to protease degradation. This technique 
has been successfully applied to several different 
protein targets (36,37) and the first stapled peptide 
based therapy, a long acting growth hormone 
releasing hormone (GHRH) agonist, has passed 
Phase I clinical trials, while the first anti-cancer 
stapled peptide, targeting the reactivation of p53, 
has also now entered Phase I trials (38). Peptides 
based on a helix from the Ras exchange factor 
SOS have been used to target Ras (39,40), 
suggesting that small G proteins are amenable to 
such approaches. The Ras-binding peptides 
designed so far are not selective for the GTP-
bound form of the Ras protein, although the 
stapled versions bind with a high affinity to wild-
type K-Ras and several oncogenic mutants (40). 
Here, we report the design and characterization of 
peptides based on a single helix of the RLIP76 
RBD that bind selectively to active, GTP-bound 
Ral. This work provides proof of principle that a 
single helix of RLIP76 is responsible for the 
majority of the RLIP76 interactions with Ral and 
that it is possible to use this approach to obtain 
peptides specific to the active form of a small 
GTPase. We describe stapled peptides based on 
this helix that have cell-penetrating ability and are 
biologically active. These peptides provide the 
basis for further maturation to therapeutically 
useful antagonists of Ral and Ras signalling. 
 
Results 
A peptide based on RLIP76 RBD α2 is sufficient 
to bind RalA and RalB. 
Our previously reported NMR solution structure of 
the Ral-binding domain (RBD) of RLIP76 bound 
to active, GMPPNP-loaded, RalB (33) showed that 
RLIP76 employs a coiled-coil motif to bind to Ral. 
The structure suggested that most of the key 
interactions with Ral are mediated by the C-
terminal helix (hereafter α2) of the RLIP76 RBD 
coiled-coil (Figure 1a). Indeed, 80% of the buried 
surface area in the complex involves helix α2 and 
alanine scanning mutagenesis identified more 
energetic hotspots within this helix than in α1 (the 
N-terminal helix of the coiled-coil) (17). To 
determine whether helix α2 is sufficient for 
binding to RalB, we synthesized two separate 
peptides based on the contact surfaces in helix α1 
and α2. Peptide 1 comprised the full helix α2 
sequence, residues 423-446, to encompass all of 
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the RalB-interacting residues in this helix. 
Peptide 2 incorporated residues 408-422 and 
comprises residues corresponding to the last two 
turns of helix α1 together with the short loop that 
connects α1 and α2. This peptide therefore 
includes all the contacts to RalB outside helix α2.  
Circular dichroism (CD) spectroscopy experiments 
performed on the complete RLIP76 RBD resulted 
in a characteristic α-helical spectrum with minima 
at 208 and 222 nm (Figure 1b). The helical content 
calculated from the CD spectra was 77% (Figure 
1c), in agreement with the 78% seen in the 
structure of free RLIP76 RBD ((33), pdb code: 
2kwh). CD analysis of the two synthetic peptides 
revealed that Peptide 1 was 50% helical in 
solution, while Peptide 2 was only 4% helical 
(Figure 1b,c). The helical content of the residues 
equivalent to Peptides 1 and 2 in the context of the 
entire RBD is 96% and 53% respectively. 
Therefore the helices in both peptides are 
destabilized when they are not in the context of the 
coiled-coil. Peptide 1 however, clearly retains 
some helical propensity in isolation, and 
presumably is in equilibrium between structured 
and unstructured states. Conversely, Peptide 2 
shows little propensity to form any helix when it is 
removed from the coiled-coil, and its CD spectrum 
is characteristic of a random coil (Figure 1b). 
The binding of the RLIP76 RBD, Peptide 1 and 
Peptide 2 to RalB was investigated using 
isothermal titration calorimetry (ITC). The 
RLIP76 RBD coiled-coil bound to RalB with an 
affinity of 1.9 µM (Figure 2a, Table 1) and with a 
similar affinity (4.6 µM) to RalA•GMPPNP (data 
not shown). The interaction appears to be driven 
by a relatively large, favourable enthalpic term, 
which counteracts the unfavourable entropy loss 
that occurs when the two domains come together.  
Peptide 1 also bound to RalB but with a lower 
affinity. The Kd was around 30 µM, an order of 
magnitude weaker than the full coiled-coil domain 
of RLIP76 RBD (Figure 2b, Table 1). In contrast, 
Peptide 2 showed no heat changes when titrated 
into RalB under the same conditions, supporting 
the idea that most Ral binding contacts occur 
through RLIP76 RBD α2, (Figure 2c). 
Encouragingly, while ITC showed that Peptide 1 
also bound to RalA, with Kd 43 µM (Figure 2d, 
Table 1), it showed no interaction with the Rho-
family GTPase Rac1 (Figure 2e), indicating that 
binding of this single helix is selective for Ral 
small G proteins.  
The ITC data for Peptide 1 revealed that when this 
peptide binds to RalA and RalB the ΔS term is 
positive, in contrast to the entropy loss that was 
observed when RLIP76 RBD and Ral proteins 
interact. This favourable entropy change increases 
the binding affinity, which would otherwise be 
drastically reduced by the smaller enthalpic gain 
when the peptides bind (Table 1).  
A peptide based on RLIP76 RBD α2 binds to 
RalB on the same interface as RLIP76. 
Given the altered thermodynamics of the 
interaction, it is possible that Peptide 1 binds to a 
different region of the Ral proteins. To ascertain 
whether Peptide 1 binds in a similar manner as the 
RLIP76 RBD, 1H-15N HSQC NMR experiments 
were used to map the binding surface on RalB 
utilized by Peptide 1. HSQC spectra of uniformly 
15N-labelled RalB·GMPPNP were recorded both 
alone and in the presence of increasing amounts of 
Peptide 1. Addition of Peptide 1 caused several 
RalB peaks to shift and in some cases to lose 
intensity (Figure 3a), which is consistent with a 
mixture of fast and intermediate exchange on the 
NMR timescale. This is likely to be due to the 
switch regions of RalB undergoing conformational 
exchange when in the complex with the peptide. A 
titration was performed at a range of RalB:Peptide 
1 ratios from 1:0 to 1:8, which, along with the 
previously reported backbone assignment (41), 
allowed most of the crosspeak positions to be 
tracked. The majority of the peaks in the peptide 
complex were assigned and their positions 
compared with those of the peaks corresponding to 
the same residues in the RalB-RLIP76 RBD 
complex. Comparison of the HSQC spectra of free 
RalB·GMPPNP with RalB·GMPPNP-Peptide 1 
and RalB·GMPPNP-RLIP76 RBD shows that 
those peaks that shifted tended to move in the 
same direction in both complex spectra (Figure 
3a). For example, Arg52, which experienced a 
relatively large shift, moved in the Peptide 1 
complex to a position very close to that of the 
Arg52 crosspeak in the RLIP76 RBD complex. 
The peak positions in free RalB·GMPPNP and in 
RalB·GMPPNP-Peptide 1 were used to calculate 
the overall chemical shift change (Figure 3b). The 
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changes are concentrated in the N-terminal half of 
the RalB protein, which includes the two 
nucleotide-sensitive switch regions. The residues 
that experienced a significant shift change (larger 
than the standard deviation of all changes) were 
mapped onto the RalB structure (Figure 3c). These 
included several residues that are unlikely to be 
directly contacting Peptide 1, because they are 
buried in the free RalB structure (42). These shift 
changes, which also occurred when the RLIP76 
RBD was titrated into RalB, are indicative of 
subtle conformational rearrangements that are 
often observed when small G proteins such as 
RalB bind to their effectors (DO and HRM, 
unpublished observations). The solvent 
accessibility of the RalB·GMPPNP residues was 
assessed using NACCESS (43). Residues that are 
shifted, and are at least 50% solvent exposed, are 
highlighted in Figure 3c. All of these residues are 
within, or close to, the switch regions and most of 
them are in direct contact with the C-terminal 
helix of RLIP76 RBD in the complex (Figure 
3c,d). Two residues that shift but do not contact 
RLIP76 are Val40RalB and Glu41RalB. These are at 
the beginning of switch 1, while Asp49RalB at the 
opposite end of the same switch is in direct 
contact. The structure and dynamics of the whole 
switch region changes in the RLIP76 complex and 
the chemical shifts of Val40 and Glu41 are likely 
to be sensitive to this. The crosspeaks for most of 
switch 1 are not visible in the spectra of free 
RalB·GMPPNP, so it is not possible to see 
changes for other residues within the same loop. 
Overall, the correlation between crosspeak 
positions in the RalB·GMPPNP-Peptide 1 and 
RalB·GMPPNP-RLIP76 RBD spectra, along with 
the positions of the residues that exhibit the largest 
chemical shift changes indicate that the contact 
surface for Peptide 1 on RalB is identical to that of 
the RLIP76 RBD helix α2. 
Design and synthesis of RLIP76-based stapled 
peptides 
Having established that an RLIP76 RBD-based α2 
peptide could selectively bind to Ral in an 
analogous manner to the RLIP76 RBD, we sought 
to improve its binding affinity. Chemical stapling 
of peptides has been shown to increase their 
helicity and often enhances their binding to target 
proteins (36). Stapled peptides were synthesized 
using a well-established solid-phase peptide 
synthesis method for incorporation of all-
hydrocarbon staples (44). Two unnatural amino 
acids containing α-methyl, α-alkenyl side-chains 
were introduced into the peptide sequence, and the 
staple covalently formed by ruthenium-catalysed 
ring-closing metathesis (Figure 1a,c). Five stapled 
peptides were designed based on RLIP76 RBD α2 
(SP1-SP5), as Peptide 1 had already been 
confirmed to bind Ral. One stapled peptide was 
also designed based on RLIP76 RBD helix α1 
(SP6) to investigate whether increased secondary 
structure in Peptide 2 could facilitate Ral complex 
formation. Examination of the RalB·GMPPNP-
RLIP76 RBD structure (33), together with 
computational and experimental alanine scanning 
mutagenesis data (17) revealed those 
RLIP76 RBD residues that were the most 
important for Ral binding (Figure 1a). These 
included three residues in helix α1 (Leu409, 
His413 and Leu416) and five residues in helix α2 
(Leu429, Trp430, Arg434, Thr437 and Lys440). 
Individual mutation of any of these residues to Ala 
reduced the binding affinity of RLIP76 RBD for 
RalA or RalB more than 5-fold (17). These vital 
binding residues were retained in the peptide 
sequences and the chemical staples were 
positioned on the opposite face of the α-helix to 
allow these key residues to drive complex 
formation (Figure 1a,c). Peptides were synthesized 
with different staple lengths and staple positions to 
enable screening for optimum binding. SP1, SP2 
and SP3 contained a single i, i+4 staple, which 
was placed in various positions along the α2 helix. 
SP6, based on helix α1 and the interhelix loop, 
only included three turns of α-helix. This peptide 
also contained a single i, i+4 staple, however only 
a single staple position was tested, as other 
positions would potentially disrupt the structure of 
the loop. SP4 and SP5 were also based on helix 
α2: SP4 contained one i, i+7 staple, and SP5 was 
doubly stapled, with two i, i+4 linkages (Figure 
1c). All peptides were acetylated at the N-terminus 
and included a C-terminal amide bond. Following 
purification, the helicity of the stapled peptides 
was determined by CD spectroscopy (Figure 1b,c). 
Incorporation of the staples increased the helicity 
of most of the RLIP76 RBD peptides compared to 
their unstapled counterparts: SP1, SP3, SP4 and 
SP5 showed extremely high helicity (80-90%), 
much more than the unstapled Peptide 1, and close 
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to the ~90% expected if the peptides were to adopt 
the same structure as α2. SP2 was the least helical 
of the α2-based stapled peptides, and had the same 
helicity as the unstapled Peptide 1, suggesting that 
the staple at this position does little to stabilize the 
helix. Stapling of the unstructured Peptide 2 also 
significantly increased its helicity, although SP6 
was still only 57% α-helical, less than the ~75% 
expected if the peptide had the same structure as 
the equivalent sequence in the RLIP76 RBD. 
 
SP1 binds to RalB with increased affinity 
compared to unstapled Peptide 1. 
Stapled peptide binding to RalB·GMPPNP was 
investigated using ITC, as for the unstapled 
peptides (Figure 4). All of the stapled peptides 
based on the RLIP76 RBD α2 sequence (SP1-
SP5) were able to bind RalB but the stapled 
analogue of α1, SP6, did not exhibit any heat 
changes, despite its increased helicity. This 
suggests that the binding interactions made 
between RLIP76 RBD α1 and RalB are not strong 
enough to enable complex formation in the 
absence of the α2 helix. The α2-based peptides 
SP3, SP4 and SP5 bound RalB with Kd 16-53 µM 
(Table 1), which are similar to the affinity of the 
unstapled Peptide 1 (30 µM). Compared with 
Peptide 1, SP1 and SP2 displayed enhanced 
affinity, with Kd values 4.7 µM and 10.3 µM 
respectively. 
The binding of the stapled peptides was 
characterized by similar ΔH terms (of the order of 
1 kcal/mol), implying that the nature of the 
interfaces may be similar (Figure 4, Table 1). The 
exception was SP4, which has the longer, i, i+7 
staple, and was characterized by very small heat 
changes and non-reproducible data in the ITC 
experiments. This implies that SP4 binds using 
predominantly hydrophobic interactions and 
therefore may not utilize the same binding mode 
as the other peptides. Similarly, SP5, which has a 
double staple, bound weakly, and the data could 
not be accurately fitted. The stapled peptides had 
more favourable entropy of binding compared 
with the unstapled Peptide 1, and the enhanced 
binding of SP1 and SP2 is entirely due to the 
increase in ΔS. 
SP1 is selective for active Ral and binds 
competitively with Ral effector proteins 
As SP1 bound to RalB with the highest affinity, 
this peptide was taken forward for further 
investigation. N-terminally fluorescein labelled, 
FITC-SP1 and FITC-Peptide 1, were synthesized 
for fluorescence polarization (FP) assays. The use 
of an orthogonal assay to measure peptide binding 
was also useful to validate the results obtained 
with ITC. Direct binding FP assays showed that 
SP1 bound RalB with a Kd value of 5.6 µM, 
similar to that measured by ITC (Figure 5a). The 
binding of Peptide 1 measured by FP was too 
weak to obtain an accurate fit (Figure 5b), which 
placed the Kd at ≥ 50 µM, in line with the value 
measured by ITC (Table 1). We also tested the 
binding of FITC-SP1 to RalA·GMPPNP and 
found that it bound but with a slightly lower 
affinity than to RalB·GMPPNP, with a Kd of 14.2 
µM (Figure 5c). This is in agreement with the 
lower affinities that we observed when unstapled 
Peptide 1 or the RLIP76 RBD were titrated into 
RalA·GMPPNP in ITC experiments. 
To investigate the specificity of SP1 for Ral 
proteins, we examined its ability to bind to R-Ras, 
which is another small G protein in the Ras-
family. This is a stringent test of specificity, since 
R-Ras and RalB are both in the Ras family, have a 
sequence homology of 64 %, and are conserved in 
the effector binding region (Figure 3d). FITC-SP1 
bound to R-Ras·GMPPNP but with an affinity of 
30 µM, 5-fold weaker than RalB (Figure 5a). The 
affinity of FITC-Peptide 1 for R-Ras·GMPPNP 
could not be determined accurately but again was 
weaker than that of Peptide1 for RalB·GMPPNP 
(Figure 5b).  
Attempts were made to perform chemical shift 
mapping experiments with SP1 and 15N-labelled 
RalB·GMPPNP, analogous to those shown in 
Figure 3. It was however, not possible to find 
conditions in which both SP1 and RalB were 
stable at sufficiently high concentrations for NMR. 
As the peptides were designed based on helices 
from a Ral effector, and the NMR chemical shift 
mapping had suggested that Peptide 1 was binding 
close to the switch regions, we reasoned that the 
peptide binding should be nucleotide dependent. 
Nucleotide-dependent binding of SP1 to Ral 
would also imply that SP1 binds to Ral in the same 
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regions as Peptide 1. When RalA·GDP was 
titrated into FITC-SP1 (Figure 5c) no significant 
binding was observed, indicating that SP1 binding 
to Ral is dependent upon the GTP-bound 
conformation of the switch regions. Therefore, as 
is the case for GTPase effector proteins, SP1 
preferentially binds active, GTP-bound Ral over 
the inactive, GDP-bound state. 
To determine whether effector proteins could 
compete with SP1 for binding to RalB, a 
competition FP assay was performed. Increasing 
amounts of the RLIP76 RBD were titrated into a 
pre-formed complex of RalB·GMPPNP-
FITC-SP1. The resulting decrease in FP signal 
(Figure 5d) indicates that FITC-SP1 and the 
RLIP76 RBD bind competitively to 
RalB·GMPPNP. The RLIP76 RBD was able to 
fully displace FITC-SP1 with an IC50 of 2.0 µM, 
which is comparable with the Kd for 
RalB·GMPPNP-RLIP76 RBD measured by ITC. 
This indicates that the peptide and RLIP76 RBD 
use the same interface to bind RalB·GMPPNP. We 
were interested in exploring whether other Ral 
effectors could also compete with SP1 for 
RalB·GMPPNP binding. The Sec5 RBD binds to 
Ral proteins with a higher affinity than RLIP76: 
both RalA and RalB bind Sec5 RBD with a Kd of 
~100 nM (42). When the Sec5 RBD was titrated 
into the RalB·GMPPNP-FITC-SP1 complex, the 
FP signal was reduced. However, Sec5 did not 
cause complete loss of the FP signal even at high 
concentrations, and resulted in an IC50 of 8.2 µM, 
i.e. much higher than its Kd. This indicates that 
although there is some overlap in the binding sites 
of SP1 and Sec5 RBD, even at high Sec5 
concentrations some binding remains between 
FITC-SP1 and RalB·GMPPNP. This can be 
explained by the observation that the 
RLIP76 RBD binds to both switch regions of RalB 
(33), whereas Sec5 RBD only contacts switch 1 
(18). Therefore the Sec5 RBD binding to switch 1 
is unable to displace SP1 completely, which can 
continue to contact switch 2 even in the presence 
of Sec5. Taken together, the evidence indicates 
that FITC-SP1 binds in an analogous manner to 
α2 of the RLIP76 RBD, which contacts both 
switch regions and cannot be fully displaced by 
the Sec5 RBD. 
 
FITC-SP1 can enter mammalian cells 
For stapled peptides to have experimental or 
therapeutic value they must be able to access their 
intracellular targets. To assess the cell penetrating 
properties of RLIP76 RBD-based peptides, we 
monitored the cellular uptake of FITC-Peptide 1 
and FITC-SP1 using confocal microscopy. 
HEK293T cells were treated with 10 µM 
FITC-Peptide 1, FITC-SP1 or FITC alone, 
overnight at 37 °C and fixed with formaldehyde 
before imaging (Figure 6a,b). Consistent with 
previous studies on stapled peptides (36,37,45,46), 
robust penetration of SP1 into cells was observed. 
In contrast, uptake of FITC alone or the 
unconstrained FITC-Peptide 1 was not detectable 
in any cells. These data also indicate that the 
stapled peptide is stable for at least 16 hours. 
Single-cell images indicate that FITC-SP1 
localizes throughout the cell, entering the nucleus 
as well as diffusing through the cytosol (Figure 
6b). Encouragingly, the cells treated with 
FITC-SP1 were observed to be in a similar state of 
health and confluency as the control cells, 
suggesting that the peptide is not inherently toxic. 
Once we had established cellular uptake of SP1 we 
wanted to confirm that the inhibition of Ral-
effector interactions that we had already 
demonstrated in vitro for the stapled peptide were 
maintained in a cellular context.  To judge this, we 
examined the ability of SP1 to inhibit co-
immunoprecipitation of RalB with an effector 
protein. We incubated HEK293T cells in the 
presence or absence of SP1, immunoprecipitated 
endogenous RalB and immunoblotted for the 
presence of Sec5. SP6, the stapled helical peptide 
based on helix α1, which showed no heat changes 
in ITC experiments (Figure 4f), was used as a 
control. We used Sec5 to investigate whether SP1 
acts as a pan-RalB inhibitor in cells with similar 
activity to that which we had already observed in 
vitro. Endogenous Sec5 was observed to co-
immunoprecipitate with RalB in the absence of 
peptide (Figure 6c) but the interaction was almost 
completely inhibited by SP1, 24 hours after 
treatment. Interestingly, SP6 also appeared to 
attenuate the RalB-Sec5 interaction, although not 
as strongly as SP1. This suggests that even though 
it showed no heat changes in the ITC experiments, 
SP6 exhibits some low affinity binding to RalB. 
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We can therefore conclude that SP1 enters cells 
and once it is intracellular it retains the ability to 
inhibit RalB interactions with its downstream 
effector proteins. 
SP1 can inhibit RalB-driven autophagosome 
assembly in cells 
We next sought to examine whether SP1 retained 
the biological activity of the RLIP76 RBD and 
could interfere with Ral signalling in cells. 
Previous studies have demonstrated the 
involvement of RalB in nutrient deprivation-
induced autophagosome assembly through its 
interaction with the downstream effector Exo84 
(35). RalB is localized to nascent autophagosomes 
and is activated in response to nutrient deprivation. 
In its active conformation, RalB·GTP binds 
directly to its effector Exo84, inducing the 
assembly of catalytically active ULK1 and 
Beclin1-VPS34 complexes on the exocyst, which 
drive isolation membrane formation and 
maturation. Thus RalB signalling is necessary and 
sufficient to engage autophagy. In contrast, RalA 
has no involvement in the control of autophagy; so 
monitoring the effects of SP1 on autophagy 
specifically reveals the effects of its inhibition of 
RalB. Autophagosome assembly can be monitored 
through the loss of the marker LC3, which is first 
recruited to autophagosomes prior to its 
degradation in autophagolysosomes (Figure 7a,b). 
Exogenous expression of the RLIP76 RBD 
inhibits RalB-Exo84 complex formation and 
prevents autophagosome formation and maturation 
(35). To investigate whether SP1 had the same 
effect, HeLa cells stably expressing GFP-LC3 
were treated with the cell-permeable SP1 for 
24 hours and assayed for autophagosomal flux 
with quantitative microtiter plate-based assays. 
SP1 but not SP6 exposure resulted in dose-
dependent inhibition of GFP-LC3 turnover that 
was not reversed by nutrient starvation, indicating 
robust inhibition of autophagosomal maturation at 
20µM SP1 (Figure 7c).  These observations imply 
that SP1 is able to penetrate cells and achieve a 
sufficiently high intracellular concentration to bind 
to RalB and inhibit its biological activity. To 
confirm that the effects observed were due to the 
interaction between SP1 and RalB, the localization 
of TFEB was evaluated. TFEB is a direct 
mTORC1 substrate that is sequestered in the 
cytosol under nutrient replete conditions (47,48). 
Nutrient starvation results in mTORC1 
inactivation and consequent translocation of TFEB 
to the nucleus where it induces adaptive gene 
expression programs. TFEB localization was 
unimpaired in SP1-treated cells (Figure 7d), 
demonstrating that the SP1-dependent inhibition 
of autophagosome maturation is unlikely to be 
through non-selective disruption of cellular 
responses to nutrient deprivation.   
 
Discussion 
The Ras signalling pathway has been proven to be 
a key driver of numerous cancers and is therefore 
a crucial anti-cancer drug discovery target. The 
difficulty in obtaining drug-like compounds that 
inhibit Ras itself has led to broader targeting of 
downstream Ras pathways, including the kinases 
Raf and PI3K. These efforts have been hampered 
by unexpected discoveries: the first class of Raf 
inhibitors turned out to activate the pathway in 
Ras-driven cancers (10), while MEK and PI3K 
inhibitors are also less efficacious due to the 
presence of feedback loops and poor tolerance 
(11). The third main Ras-driven signalling 
pathway activates the small GTPases RalA and 
RalB through the RalGEFs. Evidence indicates 
that this pathway is equally important in 
conveying signals from oncogenic Ras to drive 
tumourigenesis and is therefore a valuable 
therapeutic target (1). This signalling route has not 
been as extensively studied as the Raf and PI3K 
systems and does not exhibit as many 
conventionally exploitable targets. In fact until 
very recently there have not been any chemical 
inhibitors reported that act on this branch of the 
Ras cascade. Recently, a potential allosteric site 
was identified on RalA and used as the basis for a 
virtual small molecule screen. This generated hits 
that inhibit RalA and RalB by binding to the small 
G proteins in their GDP-bound form, locking them 
in their inactive conformation. These molecules 
have biological activity in cell lines and are also 
efficacious in mouse xenografts driven by K-
Ras/Ral, demonstrating the utility of Ral inhibition 
for therapeutic gain and representing an exciting 
step forward in cancer therapeutics (32). Here, we 
have used our structure of the RalB-RLIP76 RBD 
complex to design and synthesize all-hydrocarbon 
stapled peptides that bind to both RalA and RalB 
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in the active, GTP-bound conformation and 
compete with their effector proteins.  
We used ITC to determine the affinities and 
thermodynamics of binding of the peptides. 
Interestingly, we obtained a Kd of 1.9 µM for the 
RalB·GMPPNP-RLIP76 RBD complex by ITC, 
10-fold higher than the Kd of 184 nM that we had 
previously determined by scintillation proximity 
assay (SPA) (33). There are several likely reasons 
for these differences. Firstly, different techniques 
used to determine affinities often yield different Kd 
values. This has been shown for other Ral-effector 
complexes, for example RalA·GMPPNP binding 
to Sec5 RBD had a Kd of 137 nM measured by 
ITC (18) but a Kd 10 nM by SPR (19)). We also 
found that Cdc42·GMPPNP binding to PAK gave 
lower affinities with ITC (Kd 150 nM) than SPA 
(Kd 10 nM) (49)). The difference in the RalB-
RLIP76 RBD affinity may also be affected by the 
use of the nucleotide used in the different 
experiments. In the ITC experiments, RalB was 
bound to the nucleotide analogue GMPPNP, while 
SPA utilized 3H-labelled GTP. All the peptides 
synthesized in this study were examined for 
binding by ITC, so their relative values can be 
compared. Furthermore, the affinities measured 
using FP for the peptides were similar to those 
obtained by ITC, allowing comparison between 
the affinities measured with these techniques. 
We have shown that a peptide based on a single 
helix from RLIP76 (Peptide 1) is sufficient to bind 
Ral, albeit with approximately 14-fold weaker 
affinity than the full coiled-coil domain that 
comprises the RBD. NMR mapping indicates that 
Peptide 1 interacts with RalB at the same binding 
interface as RLIP76 RBD, so the reduction in 
affinity is due to the smaller peptide making fewer 
contacts with Ral, rather than to a different mode 
of binding. ITC was used to measure the affinities 
but it also yielded useful information about the 
thermodynamics of the interactions (Table 1). The 
interaction between RalB·GMPPNP and the full 
RLIP76 RBD is driven solely by a large negative 
ΔH, as the entropy change is in fact unfavourable. 
An analysis of the interactions between the two 
proteins suggests that the interface comprises a 
mixture of hydrogen bonds/salt bridges and 
hydrophobic interactions, which involve both α-
helices of the RLIP76 RBD. Presumably the 
hydrophobic interactions between the two proteins 
are not sufficiently numerous to offset the entropy 
loss on association. In contrast, when the peptides 
bind, the enthalpy term is reduced 10-fold or more 
(although it is still negative) but the entropy term 
is now positive (Table 1). Some of the change in 
enthalpy compared to the full RBD binding is 
likely to be due to the loss of the three hydrogen 
bonds involving helix α1 predicted from the 
structure: His413(Nε)-Tyr82(OH), Leu416(CO)-
Asn81(Hδ), Gln417(Hε)-Asp74(CO), which are 
not present in the peptide complexes. The switch 
in the entropic term from negative in the full RBD 
to positive in the peptides is probably due to the 
larger number of exposed hydrophobic sidchains 
in the peptides, which lowers the entropy of the 
free peptides. The stapled peptides bind more 
tightly than the unstapled versions because the 
entropic term is even more favourable and apart 
from SP4 (which gave poor, non-reproducible 
data), ΔS is proportional to the affinity (Table 1). 
Peptide stapling reduces the entropic cost of the 
peptide folding upon binding by forcing the helix 
to be pre-formed. The subtle differences between 
the stapled peptides may be due to slight 
conformational differences when the staple 
position is moved. These could change the extent 
of burial of sidechains in the interface.  
The helicity of the stapled peptides shows little 
obvious correlation with their affinities. The 
helical content of SP1, SP3, SP4 and SP5 is almost 
equivalent, while SP2, which has the second 
tightest binding, is no more helical than Peptide 1 
(Figure 1c). The helical content estimated by CD 
is, however, the average in solution. It is 
reasonable to assume that Peptide 1 exists in an 
equilibrium between helical and unstructured, and 
that, as it is 50% helical, the two populations are 
approximately equal. Binding to RalB then pushes 
the equilibrium to the helical state. In SP2 on the 
other hand, the stapling ensures that the centre of 
the peptide is helical, so that at least part of the 
peptide is helical all of the time. This shorter helix 
would then act as a nucleation site for the 
formation of the remainder of the helix on binding. 
For peptides such as SP3, which exhibits high 
helicity but low affinity, we can speculate that the 
staple position has locked the sidechains into a 
position where they can no longer make 
favourable interactions with RalB. It is noteworthy 
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that SP3 and SP4, neither of which binds tightly, 
both have their staple positioned behind the Trp 
within the peptide. Mutation of Trp430 in the 
context of the RLIP76 RBD knocks out binding 
completely (17) and the structure shows that this 
residue makes extensive interactions with RalB 
(33). It is likely that the rigidity imposed by 
stapling across the back surface of this Trp 
restricts at least some of these interactions. 
The most potent RLIP76 RBD α2-based stapled 
peptide (SP1) bound to RalB with a 5-fold 
increase in affinity over the unstapled peptide. 
Previously published studies on stapled peptides 
have reported affinity increases between 2- and 
100-fold, depending on the protein target (36,37). 
The 5-fold increase noted here therefore, is rather 
a modest effect. However, in this case the native 
unstapled peptide is already significantly helical 
(unlike many other peptides) and has a reasonable 
affinity compared with that of the RLIP76 RBD. 
The final affinity of the best stapled peptide is 
only ~2.5-fold weaker than the complete 
progenitor domain, the RLIP76 RBD and, as such, 
SP1 provides an excellent starting point for further 
optimization. Interestingly, the small molecule 
inhibitors identified for Ral also have a Kd of 
approximately 5-8 µM and are still effective 
inhibitors in both cell culture and animal models 
(32). These low µM Kd values reflect the difficulty 
in designing chemical inhibitors for Ral proteins 
and highlight the importance of our peptide.  
Constrained peptides have already been designed 
to bind to small G proteins of the Ras superfamily. 
Ras itself has been targeted with stabilized α-
helical peptides that were based on a helix from 
the exchange factor SOS. Peptides stabilized by 
the hydrogen bond surrogate method (39) bound to 
Ras⋅GDP with a Kd of 160 µM, 10-fold weaker 
than the catalytic domain of SOS. On the other 
hand, hydrocarbon-stapled peptides based on the 
same SOS helix bound to K-Ras with an affinity 
of around 0.1 µM but were not selective for the 
GTP-bound form, as expected for a peptide based 
on an exchange factor (40). Hydrocarbon-stapled 
peptides based on Rab-binding proteins, including 
effectors and exchange factors, have been 
screened against several members of the Rab small 
G protein family. Several of these bound 
preferentially to nucleotide-free Rabs, but a Kd of 
22 µM was obtained for the most potent stapled 
peptide with GMPPNP-bound Rab8a, which was 
also selective for this Rab isoform (50).  
We exploited the helical nature of an effector 
protein in this work to target specifically the GTP-
bound form of the Ral proteins, on the basis that 
this is the form that is downstream of oncogenic 
Ras and so is active in a disease scenario. We have 
shown that this is a viable approach, since the 
highest affinity peptide was indeed specific for the 
active Ral proteins and showed no interaction with 
the GDP-bound forms. Can this approach be 
applied to other small G proteins? For Ras itself it 
is difficult to envisage, since all the known 
effectors utilize an intermolecular β-sheet to bind 
the G protein (reviewed in (34)). Apart from Ras, 
the largest structural class of effectors for small G 
proteins is actually those that bind using a helical 
pair. We have recently classified these into six 
subclasses, based on their helix orientations, which 
cover interactions between effectors and members 
of the Ras, Rho, Arf and Rab families (34). In 
several cases one of the helices dominates, making 
the majority of the interactions with the 
nucleotide-sensitive switch regions and therefore 
making the relevant small G proteins open to this 
approach to inhibitor design. Representative 
examples from 5 of the 6 classes where one helix 
makes most interactions are: RalB-RLIP76; Arf1-
GGA; Rac1-PRK1; Arl1-Arfaptin1 and Arf6-JIP4. 
Stabilized helical peptides based on effectors may 
therefore be useful starting points for design of 
molecules that bind (and inhibit) members of the 
Arf and Rho families as well as Rab and Ral. 
The stapled peptides that we have designed bind to 
the nucleotide sensitive switch regions of Ral. 
These regions, as well as being responsible for 
effector binding, are the sites of interaction with 
the GEFs and GAPs, the regulators of the G 
proteins. We tested whether SP1 bound 
competitively with Ral effectors, and found that it 
could be fully displaced by RLIP76 and only 
partially displaced by Sec5. This indicates that 
SP1 binds to both switch 1 and switch 2. The 
recent structure of Ral with a GEF protein (Rlf) 
shows that switch 2 is involved in the GEF 
interaction and is also important for Ral vs Ras 
selectivity (25). There are currently no structures 
of Rals in complex with cognate GAPs, but the 
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RalGAP proteins have closest homology with 
RapGAPs, and a Rap1b-Rap1GAP complex shows 
that both switch regions of the Rap protein are 
involved in the interaction (51). As our peptides 
do not bind to the GDP-bound form of Ral, they 
should not compete with GEF proteins for binding 
but they are likely to bind competitively with the 
GAP proteins. This implies that they would not 
prevent Ral proteins being activated (i.e. becoming 
GTP-bound) in the cell but as the peptides would 
be competitive with GAP binding they could 
prevent deactivation. Nevertheless, we have 
demonstrated here the important overall effect of 
SP1 in cells, which is to prevent Ral signalling by 
competing with effector binding. Furthermore, 
GTP-specific peptides would be particularly useful 
in cells that have reduced RalGAP activity, for 
example invasive bladder cancer cell lines (27). 
Interestingly, we found that RalA·GMPPNP 
binding to both Peptide 1 and SP1 was of a lower 
affinity than RalB·GMPPNP binding to the same 
peptides. The peptides were designed based on the 
structure of RalB·GMPPNP with RLIP76 RBD. 
Although the RalA·GMPPNP and RalB·GMPPNP 
sequences are identical in the regions that bind to 
RLIP76, mutagenesis of the RLIP76 RBD has 
revealed some isoform differences (17). Of 
interest is the observation that mutation of Leu412 
in helix α1 to Ala reduces RalA binding 4-fold but 
does not affect RalB binding. This implies that 
helix α1 may contribute more to RalA interactions 
than to RalB binding and raises the exciting 
prospect that it might be possible to design Ral-
isoform specific inhibitors. We also found that the 
related G protein R-Ras was able to bind to SP1, 
albeit with a reduced affinity. The binding of R-
Ras is not surprising when considering the 
sequence identity between these two members of 
the Ras family. Of the 14 residues that contact 
helix α2 in the structure (Figure 3d and (33)) 11 
are identical or represent conservative 
substitutions in R-Ras. Only Ala48, Arg52 and 
Ser85 are not conserved in R-Ras. Ala48RalB 
backbone forms a hydrogen bond with the 
sidechain of Gln433RLIP76: the replacement of Ala 
by Glu in R-Ras should not prevent this directly, 
although it may alter the conformation of switch 1. 
Arg52RalB forms a hydrogen bond with the 
backbone of the RLIP76 coiled coil and makes 
contacts with RLIP76 residues Arg434, Thr437 
and Ala438. Replacement of Arg52 by the smaller 
sidechain of Thr in R-Ras would lead to a 
rearrangement of these interactions. Finally, 
Ser85RalB forms a hydrogen bond with 
Glu427RLIP76. This would not be able to form when 
R-Ras binds to RLIP76, because it has an Ala at 
this position. Therefore the selectivity of SP1 for 
Ral proteins over R-Ras probably lies in just two 
residues in Ral, Arg52 and Ser85. These residues 
also both experience chemical shift changes when 
SP1 binds and hence contact SP1 directly. 
Importantly, SP1 was able to enter mammalian 
cells, confirming its potential for use as a chemical 
probe and as a starting point for designing 
therapeutic peptides. The ability of hydrocarbon 
staples to enhance cell penetration is perhaps their 
most important attribute. Several classes of cell 
penetration enhancement sequences (CPPs) have 
been identified and successfully employed (52). 
Enhancement by chemical stapling appears to be 
due to an increase in the overall hydrophobicity of 
the peptide as a result of the chemical clamp, and 
is sequence independent. Cell penetration is likely 
to be further enhanced by the overall positive 
charge carried by SP1, as previous studies have 
suggested that positive charge is often favourable 
for uptake of constrained peptides into cells (36). 
A systematic study of more than 200 peptides 
showed that charges of +1 to +7 are optimal for 
cellular uptake: as SP1 has a charge of +2 it fits 
the profile of a peptide that readily enters cells 
(53). The same study showed that the mechanism 
of cell uptake of stapled peptides likely involves 
ATP-dependent endocytosis but is not dependent 
on calveolin or clathrin. Rather, it may be 
dependent on anionic cell-surface proteoglycans, 
explaining the necessity for positive charge.  
Our cellular uptake assays indicated that SP1 has a 
cellular lifetime of at least 16 hours (Figure 6). 
Furthermore, the activity assays were performed 
24 hours after peptide treatment, demonstrating 
that the peptide was effective for a minimum of 24 
hours. Similar activity assays using Peptide 1 
revealed some activity in cells after 12 hours, but 
this had fallen back to the control levels by 24 
hours, presumably due to degradation of the 
unstapled, and therefore unprotected, peptide (data 
not shown). This is borne out by the lack of signal 
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for FITC-Peptide 1 in cell penetration assays after 
16 hours.  
Once in cells, SP1 shows clear biological activity. 
We chose to use inhibition of nutrient starvation-
induced autophagocytosis as a cellular readout for 
peptide activity. RalB, but not RalA, is required 
for autophagosome biogenesis and is sufficient to 
activate autophagy. Thus, autophagosome 
biogenesis is an isoform-specific Ral controlled 
pathway, which gives a clean readout for 
inhibition of RalB activity. Our peptides were 
designed using the RalB-RLIP76 RBD structure 
and indeed have slightly higher affinity for RalB 
over RalA. In this assay, clear inhibition by SP1 
was achieved at low micromolar concentrations. 
We also demonstrated the ability of SP1 to inhibit 
the cellular interaction between RalB and its 
immediate downstream effector, Sec5 by 
inhibition of co-immunoprecipitation. We 
expected that SP1 should be able to interfere with 
multiple RalB effector interactions, due to the 
overlap of all known binding sites. RalB activates 
autophagy via its effector protein, Exo84. The 
mechanism of action of RalB in autophagy is 
known to be through initiation of vesicle 
nucleation, by assembly of the ULK1-Beclin1-
VPS34 complex directly on Exo84. Thus 
inhibition of autophagy suggests that the Exo84 
interaction is also inhibited by SP1 in cells. Taken 
together, the data demonstrate that SP1 inhibits 
RalB specific pathways via its engineered mode of 
action by acting as a pan RalB-effector complex 
inhibitor. 
 
The role of autophagy in cancer has been the 
subject of much investigation recently. In some 
contexts autophagy may suppress tumourigenesis 
but in the majority of situations autophagy is 
thought to promote tumourigeneis (54). 
Autophagy is found to be upregulated in Ras-
driven cancers and although this seems to be 
context dependent, autophagy inhibitors may well 
have utility in defined disease scenarios (55). 
Thus, the action of our stapled peptides in a 
cellular pathway important to Ras-driven cancers 
indicates their utility as both a cellular probe and 
as a potential therapeutic starting point. 
In summary, we have exploited the α-helical 
nature of the RBD of the Ral effector RLIP76 and 
rationally designed stabilized α-helical peptides 
that bind to Ral proteins and inhibit their 
interactions with downstream effectors. The 
constrained peptide displaying the highest affinity 
for RalB in vitro was also capable of entering cells 
and inhibiting RalB specific cellular functions. 
Thus this approach represents a potential strategy 
to interfere with Ras and Ral signalling, as well as 
providing a chemical tool to investigate Ral 
function in vivo. SP1 binds to Ral and competes 
with effector proteins, suggesting that it would be 
able to switch off Ral signalling completely and 
therefore contribute to the downregulation of 
oncogenic Ras. Therapeutics against Ras-driven 
cancers are desperately required; this peptide 
provides an excellent starting point for 
development of such a drug that could be used 
alone or in conjunction with Raf or PI3K 
inhibitors in a multi-pronged attack on aberrant 
Ras signalling. These data also provide proof of 
principle that small G proteins in their active 
conformation can be targeted using this strategy, 
which has ramifications for many other small G 
protein controlled pathways and therefore 
diseases. Work is ongoing in our laboratories to 
improve the affinity of the peptide and further 
explore in vivo effects. 
 
Experimental Procedures 
Peptide synthesis and characterization 
All peptides were synthesized using Fmoc-based 
solid-phase peptide synthesis (as previously 
published (44)) on Rink Amide (MBHA) resin 
(30 µmol scale). Resin was swollen using 1 mL N-
methyl-2-pyrrolidone (NMP) for 10 min, then 
Fmoc-deprotection carried out using 2 × 1.5 mL 
piperidine (25% v/v) in NMP for 10 min, followed 
by a pair of consecutive dichloromethane (DCM) 
and NMP washes. Standard amino acid couplings 
were performed with 800 µL of activated amino 
acid solution consisting of Fmoc-Xaa-OH 
(375 µL, 0.4 M, 5 equivalents), PyClock (375 µL, 
0.4 M, 5 equivalents) and N,N-
diisopropylethylamine (52 µL, 10 equivalents). 
Each residue was double coupled at room 
temperature for 2 × 1 h. Unnatural amino acid 
solutions contained Fmoc-protected amino acid 
(300 µL, 0.4 M, 4 equivalents), PyClock (300 µL, 
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0.4 M, 4 equivalents), N,N-diisopropylethylamine 
(42 µL, 8 equivalents) and were single coupled for 
2 h. Peptides containing unnatural amino acids 
were chemically stapled by reaction with 2 × 1 mL 
Grubbs’ first generation catalyst (6 mM) in 1,2-
dichloroethane at room temperature for 2 h. 
Following the final Fmoc-deprotection, peptide N-
termini were acetylated with 2 mL acetylation 
solution (4% acetic anhydride, 16% N,N-
diisopropylethylamine in NMP) for 1 h, or labelled 
with FITC with 500 µL FITC solution (82 mg 
FITC (7 equivalents), 73 µL N,N-
diisopropylethylamine (14 equivalents) in 
dimethylformamide (DMF)) overnight. Peptide 
resins were extensively washed with DCM, 
methanol and diethylether and dried in a vacuum 
dessicator overnight, before deprotection using 
95% trifluoroacetic acid, 2.5% triisopropylsilane, 
2.5% water (1.5 mL) for 2.5 h. Peptides were 
purified by HPLC and analysed using LCMS and 
MALDI. The concentrations of stock solutions 
were checked by amino acid analysis. See Table 
S1 for characterization data for all peptides 
synthesized. FAM peptides were purchased from 
Eurogentec. 
Circular dichroism spectroscopy 
CD spectra were recorded at 1 nm intervals 
between 190-260 nm using a Chirascan CD 
spectrometer with a 1 mm path length quartz 
cuvette. Three scans were recorded for each 
peptide, the data averaged and buffer background 
subtracted. Peptides were measured at 10 µM in 
20 mM phosphate buffer, pH 7.5 at 298 K. The 
helical content of each peptide was determined 
using CDSSTR, Set 7 and DichroWeb (56).  
Protein expression 
RalB (residues 1-185, Q72L), RalA (1-184, 
Q72L), and RLIP76 RBD (residues 393-446, 
C411S) were expressed and purified as described 
previously (33,41). Cultures used to express 15N 
labelled RalB were grown in MOPS minimal 
media supplemented with 15NH4Cl, as described 
previously. All protein tags were cleaved prior to 
use, as previously described (33). Exchange of 
nucleotide for GMPPNP was performed as 
described previously (49). R-Ras (residues 23-201, 
Q89L) was cloned into pET16b (Novagen) and 
transformed into BL21(DE3) E. coli. Its 
expression was induced by addition of 1mM IPTG 
for 3 hours, and the protein was purified using a 
Ni-IDA Sepharose column (GE Healthcare) and 
gel filtration (S75, GE Healthcare). 
 
Isothermal titration calorimetry 
ITC data were collected using a MicroCal iTC200 
calorimeter at 298 K in 50 mM Tris-HCl, pH 7.5, 
1 mM MgCl2. Peptide (1-2 mM) was titrated into 
protein (70 µM) in 19 × 2 µL additions with 120 s 
spacing between injections. Control experiments 
were performed by titrating peptides (1-2 mM) 
into buffer. Data were fitted using MicroCal 
Origin 7.0 software using a single-site binding 
model (N=1). All data shown are representative of 
at least two independent experiments. 
Fluorescence polarization 
Fluorescence polarization experiments were 
measured on a BMG Labtech Pherastar 
fluorimeter with excitation 485 nm and emission 
520 nm at 298 K. Solutions were made up in 
black, flat-bottomed 384-well plates with 30 µL 
total volume per well. Ral proteins were serially 
diluted (doubling dilutions) in 50 mM Tris-HCl, 
pH 7.5, 100 mM NaCl, 1 mM MgCl2 (maximum 
final concentration 50 µM) and added to the plate, 
followed by FITC-peptide (final concentration, 
10 nM). Plates were spun at 1000 g for 1 min and 
then read both immediately and after 30 min 
incubation at 298 K. Data were fitted to a single-
site binding model using non-linear regression 
analysis in GraphPad Prism 6.0 to obtain Kd values 
and their standard errors. 
 
Competition fluorescence polarization assays were 
run as above, using 10 nM FITC-Peptide 5 and 
1 µM RalB·GMPPNP in the presence of doubling 
dilutions of Sec5 or RLIP76 Ral-binding domains 
(maximum final concentration 30 µM). Data were 
fitted to a sigmoidal dose-response curve using 
non-linear regression analysis in GraphPad Prism 
6.0 to obtain Kd values and their standard errors. 
1H-15N HSQC NMR spectroscopy 
Experiments were recorded on a Bruker DRX500 
at 298 K using 200 µM 15N-labelled 
RalB·GMPPNP in 50 mM Tris-HCl, pH 7.5, 
50 mM NaCl, 1 mM MgCl2, 10% D2O. For the 
titration experiments, one, two five and eight 
equivalents of peptide were added to the protein 
solution and the spectra recorded after each 
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peptide addition. NMR data were processed using 
the AZARA package (W. Boucher, unpublished) 
and analyzed using CCPN ANALYSIS (57). 
Overall chemical shift perturbations, δ, were 
calculated using the equation: 
 
 where δ1H and δ15N are the chemical shift changes 
for the 1H and 15N dimensions respectively. 
Cellular uptake of peptides 
5 x 105 HEK293T cells were seeded into 35 mm 
glass bottom culture dishes and incubated in 1 mL 
DMEM supplemented with 10% FBS. After 24 h, 
FITC alone, FITC-labelled unstapled Peptide 1 or 
FITC-labelled stapled peptide SP1, were added to 
a final concentration of 10 µM. After 16 h the cells 
were fixed in 4% w/v formaldehyde. Images were 
acquired using a Fluoview 300 Laser scanning 
confocal microscope with a PLAPON 60X1.42 
PLan Apo oil objective and a 60 mm confocal 
aperture. Cells were excited at 488 nm and emitted 
light was detected at 510-570 nm. All images were 
recorded using the same instrument settings. 
Co-immunoprecipitation assays 
5 x 106 HEK293T cells were seeded 48 h prior to 
endpoint into 10 cm dishes (3 per condition) in 
DMEM supplemented with 10% FBS. The 
medium was aspirated and fresh DMEM (with 
10% FBS) with and without FAM-SP1 or SP6 (at 
100 µM each) was added 24 h prior to endpoint. 
The medium was then replaced with 1X EBSS 
(Earle’s Balanced Salt Solution) 90 min prior to 
endpoint. At endpoint, cells were lysed in lysis 
buffer (20 mM Tris-HCl pH 7.4, 137 mM NaCl, 1 
% Triton X-100, 0.5 % sodium deoxycholate, 10 
% Glycerol, 10 mM MgCl2, 2 mM EGTA, 1 mM 
PMSF, 50 mM NaF, 1 mM NaVO4, 80 mM β-
glycerophosphate plus EDTA-free protease 
inhibitor cocktail (Roche 04693159001)). After 15 
min lysis at 4 °C, lysates were cleared at 20,000 g 
for 20 min at 4 °C. Cell lysates were diluted with 
lysis buffer to prepare 120 µL of Whole Cell 
Lysate (WCL) (4 µg/µL) and 1400 µL of IP 
Lysate (6 µg/µL) for each condition. Endogenous 
RalB was immunoprecipitated by the addition of 
30 µL of mouse anti-RalB antibody (a kind gift 
from Larry Feig, Tufts University) to IP lysates at 
4 °C for 4 h. Protein A/G agarose beads (Santa 
Cruz Biotechnology Inc., sc-2003) were added for 
1 h at 4 °C to precipitate antibody-antigen 
complexes. Precipitated complexes were washed 
three times with lysis buffer for 5 min at 4 °C. The 
samples were then separated via SDS-PAGE and 
transferred to PVDF membranes (Immobilon-P). 
Membranes were probed by immunoblotting with 
the following primary antibodies: rabbit anti-RalB 
(Cell Signalling Technology cs-3523, lot 1) and 
mouse anti-Sec5 (a kind gift from Charles 
Yeaman, University of Iowa).  
 
GFP-LC3 fluorescence quantification and 
imaging 
72 h prior to endpoint, 8 x 103 HeLa cells stably 
expressing GPF-LC3 were plated per well of glass 
bottomed 96-well plates. Cells were plated in 100 
mL of DMEM supplemented with 10% FBS and 
grown for 48 h. 24 h prior to endpoint, the medium 
was changed with 100 mL fresh DMEM (with 
10% FBS). DMSO and Peptides were added 24 h 
prior to endpoint at final indicated concentrations 
(final concentration of DMSO per well was 1%). 4 
h prior to endpoint, cells were washed twice with 
PBS (with Ca2+ and Mg2+) and then fed with either 
100 mL of 1X (EBSS) or Serum-Free (SF) DMEM 
as indicated. At endpoint, EBSS-treated cells were 
washed once and SF DMEM-treated cells twice 
with 1X PBS (with Ca2+ and Mg2+). Cells were 
then fixed in 4% PFA in 1X PBS (with Ca2+ and 
Mg2+) for 10 min. Cells were then washed twice as 
before and then stained with 0.01% Hoechst in 1X 
PBS (with Ca2+ and Mg2+) for 20 min. Total 
fluorescence intensity for GFP and Hoechst was 
measured using the PheraStar FS plate-reader. For 
epifluorescence imaging, HeLa cells stably 
expressing GPF-LC3 were grown in 384-well 
plates in DMEM (with 10% FBS) for 48 h. The 
medium was not changed for DMEM-treated cells 
and EBSS-treated cells were starved for 2 h prior 
to live-cell imaging at 20X via the (BD) Pathway 
855 High-Content Bioimager.  
 
GFP-TFEB activation 
5 x 103 HeLa cells stably expressing GFP-TFEB 
(48) were plated in 500 µL DMEM (with 10% 
FBS) per well of 8-Chamber Lab-Tek® II 
Chambered #1.5 German Coverglass slides and 
grown overnight. 24 h prior to imaging, the 
δ = δ1H
2 + (0.15δ
15Ν
)2
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medium was changed with 265 µL fresh DMEM 
(with 10% FBS) and DMSO or peptides at final 
concentrations indicated (final concentration of 
DMSO per well was 1%). 24 h after peptide 
addition, live-cell images were acquired with an 
Andor Spinning Disc Confocal Microscope (oil 
immersion and 60X objective) under normal cell 
culture conditions (37 0C, 5% CO2). Initial images 
of fed-state cells were taken 24 h after peptide 
addition. The medium in each well was then 
changed with 265 µL 1 X EBSS and subsequent 
images were taken at the times indicated above.  
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Footnotes. 
1The abbreviations used are:  
GEF – guanine nucleotide exchange factor; GAP – GTPase activating protein; PI3K – phosphoinositide 
3-kinase; RBD – Ral-binding domain; FITC – fluorescein isothiocyanate; NMP – N-methyl-2-
pyrrolidone; LCMS – liquid chromatography mass spectrometry; MALDI – matrix assisted laser 
desorption/ionization; CD – circular dichroism; MOPS – (3-(N-morpholino)propanesulphonic acid; ITC – 
isothermal titration calorimetry; FP – fluorescence polarization; HSQC – heteronuclear single quantum 
correlation; DMEM – Dulbecco’s modified Eagle’s medium; FBS – foetal bovine serum; EBSS – Earle’s 
balanced salt solution; PMSF – phenylmethane sulphonyl fluoride; LC3 – microtubule-associated protein 
1A/1B-light chain 3 (LC3); PFA – paraformaldehyde; ULK1 – Unc-51 like autophagy activating kinase 
1. 
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Figure legends 
Figure 1: Design and synthesis of RLIP76-based peptides. (a) The structure of the RLIP76 RBD bound 
to RalB·GMPPNP (pdb: 2KWI) revealed key binding residues. RalB is coloured blue and the two switch 
regions are labelled. RLIP76 is coloured as follows: the segment of the N-terminal helix that contacts 
RalB is coloured green, the rest of the N-terminal helix is grey, the C-terminal helix is coloured pink and 
the sidechains of residues whose mutation reduced the binding to RalB more than 5-fold (17) are coloured 
yellow. The peptides synthesized are shown schematically, with the same colour coding and the staple 
represented as a single i, i+4 olefin link. (b) CD spectra of the RLIP76 RBD and the peptides generated in 
this study. (c) Sequences of the peptides used in this study and helicity calculated from analysis of CD 
data of the RLIP76 RBD and the peptides.  Several peptides were synthesized containing all-hydrocarbon 
staples of various lengths in different positions (indicated by X). Peptides 1 and SP1-SP5 were based on 
the sequence of the second RLIP76 RBD α-helix sequence; Peptides 2 and SP6 were based on the first α-
helix. The α-helicity of the peptides assessed using CD spectroscopy confirmed that several of the stapled 
peptides synthesized are more helical than the unstapled version of the peptide.  
Figure 2. Peptides corresponding to helix α2 are sufficient to bind to Ral proteins. Representative 
data from ITC experiments are shown for titrations of: (a) the RLIP76 RBD into RalB·GMPPNP; (b) 
Peptide 1 into RalB·GMPPNP; (c) Peptide 2 into RalB·GMPPNP; (d) Peptide 1 into RalA·GMPPNP; (e) 
Peptide 1 into Rac1·GMPPNP. The parameters for the fit for these individual experiments are shown in 
each panel. For the average parameters obtained from several experiments, see Table 1. 
Figure 3: Peptide 1 binds to RalB in an analogous manner to RLIP76 RBD. (a) Section of 1H-15N  
HSQC NMR spectra of 15N RalB·GMPPNP alone (blue) and in the presence of excess Peptide 1 (red) or 
RLIP76 RBD (black). Addition of Peptide 1 caused the movement of several peaks, all of which also 
shifted upon the addition of RLIP76 RBD. The changes in crosspeaks when Peptide 1 is added to RalB 
are smaller than those observed when RLIP76 RBD is added but the peaks shift in the same direction (see 
dotted lines e.g. Lys16, Val20, Lys27, Tyr51, Arg52). Peaks that do not shift when RLIP76 RBD is added 
(e.g. Asn128) do not shift when Peptide 1 is added. (b) The chemical shift changes were plotted for each 
residue of RalB. The secondary structural elements are shown above the graph, where β-strands are 
represented by arrows and α-helices by cylinders. Red lines indicate the locations of the two switch 
regions. The dashed blue line shows the position of the average chemical shift change (0.047) and the 
solid green line shows the standard deviation of the chemical shift changes (0.068) (c) RalB residues that 
shifted by more than one standard deviation upon titration of Peptide 1 are highlighted on the structure of 
RalB·GMPPNP (blue) and show that Peptide 1 binds to RalB in the same place as RLIP76 RBD α2 
(shown in pink). Residues that are shifted but which are more than 50% buried are shown as yellow 
sticks. Residues that are shifted but are solvent exposed are shown as orange spheres and are identified 
with a label. (d) Sequence alignment of RalA/B and R-Ras in the region that interacts with RLIP76 RBD. 
RalA and RalB have identical sequences in this region. Residue conservation is denoted below the 
alignment: * = identical, : = conservative substitution. Ral residues surrounded by a grey box interact with 
the N-terminal helix of RLIP76 RBD (helix α1); residues coloured magenta interact with the C-terminal 
helix of RLIP76 RBD (helix α2). The symbols above the RalA/B sequence denote residues that form 
hydrogen bonds or salt bridges involving backbone (+) or sidechain (*) atoms of RalB. The symbols are 
coloured grey for RLIP76 RBD α1 interactions and magenta for α2 interactions. Red lines indicate the 
locations of the two switch regions.  
 
Figure 4: Peptide stapling can increase affinity of RalB binding. ITC data for stapled peptides titrated 
into RalB·GMPPNP at 298 K (a) SP1; (b) SP2; (c) SP3; (d) SP4; (e) SP5 and (f) SP6. The parameters for 
the fit for the individual experiments are shown. For a summary of the parameters from several 
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experiments, see Table 1. SP5 could not be accurately fit, although the heat changes observed indicate 
that the peptide does bind. A lower limit on the Kd is given but no reliable parameters can be obtained. 
Figure 5. FITC-SP1 binding to Ral is specific, GTP dependent and competitive with Ral effectors. 
(a) Fluorescence polarization assays using FITC labelled SP1 confirm that SP1 binds RalB (Kd 5.6 ± 
0.3 µM, solid line). SP1 also binds weakly to R-Ras (Kd 30.0 ± 18.0 µM, dashed line); (b) Peptide 1 binds 
weakly to RalB and even less tightly to R-Ras. Affinity was too low for reliable fitting; (c) SP1 binds 
RalA·GMPPNP with similar affinity to RalB·GMPPNP (Kd 14.2 ± 8.2 µM, solid line) but does not show 
significant binding to RalA·GDP (dashed line); (d) Competition fluorescence polarization assays showed 
that both RLIP76 (solid line) and Sec5 (dashed line) displaced FITC-SP1 from RalB, suggesting 
FITC-SP1 binds to RalB on an overlapping surface. Data were fitted to give IC50 8.2 ± 2.6µM (Sec5 
RBD) and IC50 2.0 ± 1.2µM (RLIP76 RBD). All FP experiments were performed in duplicate and error 
bars show the standard deviation of the duplicates. 
Figure 6: FITC-SP1 can enter mammalian cells and inhibits the interaction between RalB and Sec5. 
(a) Wide-field image and (b) single-cell image of HEK293T cells treated with 10 µM FITC-Peptide1, 10 
µM FITC-SP1 or 10 µM FITC control overnight. Chemical stapling enables FITC-SP1 to penetrate the 
cell membrane and localize in both the cytosol and nucleus; (c) SP1 disrupts RalB-Sec5 interaction in 
cells. HEK293T cells were treated for 24 h with SP1 and SP6 as indicated. The numbers above the 
Western blot represent the relative intensities of the Sec5 band, normalized to the no-peptide control. 
Endogenous RalB was immunoprecipitated with mouse anti-RalB antibody. Immunoblotting was 
conducted with primary antibodies against RalB and Sec5. * marks the band specific to Sec5.  Ab, mouse 
anti-RalB antibody alone. WCL, Whole Cell Lysate. 
Figure 7: SP1 can prevent RalB-driven autophagosome assembly in HeLa cells. (a) RalB-Exo84 
dependent autophagy (b) epifluorescent images of GFP-LC3 in HeLa cells stably expressing GFP-LC3. 
Diffuse and punctate GFP-LC3 fluorescence (left panel) is quickly quenched upon recruitment to 
maturing autophagolysosomes (right panel) (c) quantitation of total GFP-LC3 fluorescence/cell detected 
under the indicated treatment conditions. Values represent population-based fluorescence-intensity ratios 
of GFP-LC3:Hoechst stain following 24 h pretreatment with peptides in GFP-LC3 HeLa cells. Error bars 
indicate standard deviation from the mean, N=4 (d) Subcellular distribution of GFP-TFEB fusion protein 
was monitored under the indicated conditions in HeLa cells stably expressing GFP-TFEB. Cells were 
treated with 20 µM SP1 and SP6. Images are representative of multiple fields of view.  
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Table 1. Summary of binding parameters obtained from ITC for RLIP76 and peptides titrated 
into Ral proteins. The value obtained from an orthogonal assay, FP, is included for the tightest 
binding peptide. 
Binding partners Kd (µM) ΔH (kcal mol-1) TΔS (kcal mol-1) Na 
RalB·GMPPNP + 
RLIP76 RBD (n = 2b) 
1.9 ± 0.07c -17.5 ± 1.8 -9.6 ± 1.8 0.9 
RalB·GMPPNP + 
Peptide 1 (n = 4) 
29.8 ± 7.3 -1.6 ± 0.6 4.6 ± 0.7 1.1 
RalA·GMPPNP + 
Peptide 1 (n = 3) 
43.0 ± 10.8 -1.8 ± 0.9 4.2 ± 0.9 1.0 
RalB·GMPPNP + SP1 (n 
= 3) 
4.7 ± 1.6 
(5.6 ± 0.3d) 
-0.7 ± 0.4 6.6 ± 0.2 1.0 
RalB·GMPPNP + SP2 (n 
= 2) 
10.3 ± 2.3 -0.8 ± 0.0 6.0 ± 0.1 1.1 
RalB·GMPPNP + SP3 
(n = 3) 
53.3 ± 17.8 -0.7 ± 0.3 5.1 ± 0.5 0.9 
RalB·GMPPNP + SP4e 50.8 -0.4 5.5 1.0 
RalB·GMPPNP + SP5 
(n = 3) 
>24 Not fitted Not fitted Not fitted 
 
a Stoichiometry 
b number of experiments  
c standard deviation of value obtained from multiple experiments 
d value obtained from FP 
e Peptide behaved poorly in assays and showed low heat changes: data from a single experiment 
only 
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Inhibition of Ral GTPases using a stapled peptide approach 
Jemima C. Thomas1,2,4, Jonathan M. Cooper3, Natasha S. Clayton1, Chensu Wang3, 
Michael A. White3, Chris Abell2, Darerca Owen1* and Helen R. Mott1* 
	  
	  
Sequence	  
Rt 
(min)	  
Calculated 
MW 
[M+H]+	  
Observed  
MW 
[M+H]+	  
Peptide 1	   LSKEERLWEVQRILTALKRKLREA 	   13.3	   3006	   3006	  
Peptide 2	   LLNSLHRDLQGGIKD 	   12.3	   1719	   1719	  
SP1	   LXKEEXLWEVQRILTALKRKLREA 	   16.9	   3041	   3041	  
SP2	   LSKEERLWEXQRIXTALKRKLREA 	   19.5	   3045	   3044	  
SP3	   LSKEEXLWEXQRILTALKRKLREA	   15.6	   3029	   3029	  
SP4	   LSKEEXLWEVQRXLTALKRKLREA	   16.0	   3057	   3057	  
SP5	   LXKEEXLWEVQRXLTAXKRKLREA 	   16.6	   3093	   3093	  
SP6	   LLNXLHRXLQGGIKD	   17.0	   1796	   1796	  
FITC-
Peptide 1	  
FITC-
βALSKEERLWEVQRILTALKRKLREA 	  
14.7	   3427	  
1714 (m/2), 
1143 (m/3)	  
FITC-
SP1	  
FITC-
βALXKEEXLWEVQRILTALKRKLREA 	   19.8	   3433	  
1144 (m/3), 
859 (m/4) 
Table S1: Characterization data for all peptides synthesised. 
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